Collaboration expands patient access to the Company’s prescription treatments through online telehealth consultations
PARSIPPANY, N.J.–(BUSINESS WIRE)–YARAL Pharma Inc. (YARAL Pharma), the U.S. generics subsidiary of IBSA (Institut Biochimique SA), a multinational pharmaceutical company headquartered in Lugano, Switzerland, today announced that its prescription topical patches are now available through UpScriptHealth’s telehealth platform. This collaboration provides patients with a convenient, direct-to-consumer option to consult with a licensed clinician and obtain prescriptions online.
Through its engagement with UpScriptHealth, a leading direct-to-patient telehealth company, YARAL Pharma is expanding access to high-quality, affordable generic medicines through innovative digital channels. By leveraging UpScriptHealth’s national telehealth network and technology platform, patients seeking YARAL Pharma’s topical patches can now access an efficient, affordable, and secure pathway to treatment.
“Partnering with UpScriptHealth allows us to provide greater access and convenience for patients while reinforcing YARAL Pharma’s focus on continuity of supply, quality, and customer service,” said Stephen Beckman, Chief Executive Officer, YARAL Pharma. “This collaboration helps us reach more people who may benefit from our topical products and reflects our goal of redefining what success looks like in the U.S. generics market.”
Through UpScriptHealth’s online platform, patients can connect virtually with licensed healthcare providers who can determine eligibility and, if appropriate, prescribe YARAL Pharma’s topical patches directly through participating pharmacies.
“UpScriptHealth has provided direct-to-consumer solutions for pharma for more than a decade and is proud to add YARAL as a new partner making YARAL’s topical patches accessible for patients,” said Peter Ax, CEO and founder of UpScriptHealth.
For more information, visit www.yaralpharma.com.
About YARAL Pharma
YARAL Pharma Inc. (Parsippany, N.J.) is the U.S. generics subsidiary of IBSA, a global pharmaceutical company headquartered in Switzerland. By focusing on people and innovating the ways they’re cared for, YARAL Pharma is proud to offer the same values and expertise of its parent company to the U.S. market. Dedicated to ensuring access to affordable authorized generics (AGs) and complex generic medicines that enhance healthcare outcomes, YARAL Pharma offers its customers high-quality products across a range of therapeutic areas, continuity of supply, and a commitment to exceptional customer service. For more information, visit www.yaralpharma.com or contact [email protected] or 866-218-9009.
About IBSA
IBSA (Institut Biochimique SA) is a Swiss pharmaceutical multinational with 20 subsidiaries across Europe, China, and the United States. Its products are available in over 90 countries, and its R&D activities focus on 10 therapeutic areas. In 2025, IBSA celebrated the 40th anniversary of its acquisition by current President and CEO, Arturo Licenziati, who has transformed the company into a multinational corporation employing over 2,300 personnel worldwide. IBSA’s growth and development can be attributed to its ability to innovate by refining well-known molecules, as well as to its commitment to looking to the future responsibly and transparently, thanks to the dedication and dynamism of its people.
About UpScriptHealth
UpScriptHealth is a direct-to-patient telehealth company providing new distribution channels for pharmaceutical and medical device brands. As the pioneering company behind the first fully compliant, online script in 2002, UpScriptHealth has helped patients access convenient healthcare and more than two million prescriptions. Powered by innovative technology and a telehealth network of hundreds of physicians, UpScriptHealth has forged successful partnerships with dozens of pharma and medtech businesses to streamline access to treatment while lowering costs. Since the launch of UpScript.com, the first digital, direct-to-patient platform for prescription medication, the company has delivered care and therapeutics for complex conditions including esophageal cancer, diabetes, migraines, blurry vision, sickle cell disease, and more. UpScriptHealth is headquartered in Scottsdale, Arizona. For more information about UpScriptHealth, visit upscripthealth.com.
YPM-1387-v2
Contacts
Media Contact
Daina Basile
Kovak-Likly Communications
[email protected]
